Idorsia Ltd. is a Swiss-based pharmaceutical company specializing in the discovery and development of innovative medicines across various therapeutic areas. With a focus on ESG principles, Idorsia aims to address unmet medical needs through the development of small molecules. The company's portfolio includes compounds targeting diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. With a medium-risk ESG score of 22.3, Idorsia is a biotech hub in Europe driving advancements in healthcare.